AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01633827
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
Trial: NCT01633827
Drug: Sedative
RxNorm normalized name: Sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
Trial: NCT03650582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo
Trial: NCT00268346
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD1839 treatment will be taken once a day PO, every day about the same time
Trial: NCT00176904
Drug: Busulfan, Cyclophosphamide, Antithymocyte Globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Trial: NCT04604184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01838902
Drug: DHA-PPQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a 3 day course of DHA-PPQ
Trial: NCT01838902
Drug: PQ (0.75)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of PQ at 0.75mg base/kg body weight
Trial: NCT01838902
Drug: PQ (0.4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of PQ at 0.4mg base/kg body weight
Trial: NCT01838902
Drug: PQ (0.2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of PQ at 0.2mg base/kg body weight
Trial: NCT01711021
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Trial: NCT04725422
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT01784133
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00353665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04576325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
Trial: NCT02554695
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous saline injection
Trial: NCT01409434
Drug: Oral Glucose Tolerance Test
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
Trial: NCT00293215
Drug: CMD-193
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
Trial: NCT00294723
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride placebo, 8mg capsule
Trial: NCT00294723
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo, 200 mcl
Trial: NCT00294723
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo, 300 mcl
Trial: NCT00193908
Drug: Sorbolene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
Trial: NCT02472392
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparitor
Trial: NCT00062140
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04161144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
Trial: NCT02271555
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
Trial: NCT03179527
Drug: Anti-Platelet Drugs
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including aspirin and clopidogrel, etc
Trial: NCT04472975
Drug: Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
Trial: NCT03179527
Drug: Lipid Regulating Drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including statins
Trial: NCT03179527
Drug: Coronary Vasodilator
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including nitrates
Trial: NCT03179527
Drug: Shuanghe Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Trial: NCT02827903
Drug: Metformin + Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: Metformin + Rosuvastatin,
Trial: NCT02827903
Drug: placebo + Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: placebo + Rosuvastatin
Trial: NCT04079218
Drug: Estradiol Vaginal Insert
RxNorm normalized name: estradiol Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
Trial: NCT04568421
Drug: Immunosuppressive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
Trial: NCT01649050
Drug: BGG492
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01649050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04498390
Drug: LY3493269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04498390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04512950
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
Trial: NCT04512950
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
Trial: NCT03917459
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Trial: NCT03917459
Drug: LCZ696 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Trial: NCT03905291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT03449082
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.5cc
Trial: NCT01665170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 1 ablet per day for 3 days
Trial: NCT00631696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00002854
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02607930
Drug: ABC/DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/50/300 milligrams (mg) tablets administered orally, once daily
Trial: NCT02607930
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg tablets administered orally, once daily, without regard to food
Trial: NCT02607930
Drug: ABC/DTG/3TC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally, once daily
Trial: NCT02607930
Drug: B/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally, once daily
Trial: NCT01601132
Drug: theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg (80mg/15ml elixir)
Trial: NCT00630370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Placebo tablets, TID, orally, 58 days
Trial: NCT00533403
Drug: MK0686
DrugBank: MK-0686 (DB12563)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01021436
Drug: Amikacin inhalation solution (BAY41-6551)
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
Trial: NCT03720353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 10 days. Capsules will mimic active treatments.
Trial: NCT03532009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use for approximately 3 months
Trial: NCT00524459
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002561
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2
Trial: NCT00029679
Drug: Gingko biloba
RxNorm normalized name: Gingko Biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04607421
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Trial: NCT04607421
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg or 500 mg Tablet
Trial: NCT04169893
Drug: Placebo (fasting)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo once in fasting condition
Trial: NCT04169893
Drug: Placebo (feeding)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo once after meal condition
Trial: NCT02405676
Drug: Prednisone,Vincristine, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
Trial: NCT02405676
Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Trial: NCT00585351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg single dose injection of normal saline (placebo)
Trial: NCT02405676
Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
Trial: NCT00450996
Drug: Topical Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03291457
Drug: Glucocorticoid Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
Trial: NCT01695070
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4mg prolonged release melatonin oral tablets twice daily
Trial: NCT02405676
Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Trial: NCT01699490
Drug: Fluoxetine + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
Trial: NCT00947427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injections
Trial: NCT04430738
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
Trial: NCT04430738
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
Trial: NCT04430738
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
Trial: NCT03796858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo as SC injection.
Trial: NCT01548872
Drug: HTK solution
RxNorm normalized name: Custodial HTK Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml/kg bolus in 2 minutes
Trial: NCT00349063
Drug: Soft contact lens multipurpose disinfection regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01569828
Drug: LCZ696A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01569828
Drug: LCZ696A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily administration of 400 mg LCZ696 for 5 days
Trial: NCT02629874
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Trial: NCT02629874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02587442
Drug: RadProtect®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
Trial: NCT02641639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline for infusion
Trial: NCT00334490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo in 5 mls distilled water
Trial: NCT02255513
Drug: HLD200
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02255513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03735121
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Trial: NCT01494688
Drug: RO5509554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
Trial: NCT00412542
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
Trial: NCT02654314
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg Melatonin nightly, beginning within 24 hours of admission
Trial: NCT02034331
Drug: Placebo Iontophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
Trial: NCT02472873
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01562795
Drug: nonsteroid anti-inflammatory drops
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonsteroid anti-inflammatory drops plus artificial tear substitute
Trial: NCT01562795
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroids plus artificial tear substitute
Trial: NCT01199432
Drug: 5-FU（intravenous infusion）+epirubicin+cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
Trial: NCT01712490
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Trial: NCT01199432
Drug: 5-FU（intravenous bolus）+epirubicin+cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Trial: NCT01199432
Drug: epirubicin+cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Trial: NCT00929357
Drug: DMARDs or Biologics
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03475732
Drug: XueBiJing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
Trial: NCT00793845
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First HDCT
Trial: NCT01999309
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
Trial: NCT01999309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
Trial: NCT04065893
Drug: Intensified medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
Trial: NCT00929708
Drug: AZD3199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation, o.d., 4 weeks
Trial: NCT00929708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation, b.i.d., 4 weeks
Trial: NCT02975271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo